Related Experiment Video

Updated: Oct 24, 2026

In vitro Enrichment of Ovarian Cancer Tumor-initiating Cells
11:37

In vitro Enrichment of Ovarian Cancer Tumor-initiating Cells

Published on: February 18, 2015

Inactivation of EGFR/AKT signaling enhances TSA-induced ovarian cancer cell differentiation

Genbao Shao1, Wensheng Lai1, Xiaolei Wan2

  • 1School of Medicine, Jiangsu University, Zhenjiang, Jiangsu 212013, P.R. China.

Oncology Reports
|April 11, 2017
PubMed

Insights

Histone deacetylase inhibitor trichostatin A (TSA) induces ovarian cancer cell differentiation by altering gene expression and cell cycle. Blocking the epidermal growth factor receptor (EGFR) pathway enhances this effect, suggesting a potential new therapy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Biology

Background:

  • Ovarian cancer is a leading cause of gynecologic cancer deaths.
  • Differentiation therapy for ovarian cancer remains poorly understood.
  • Histone deacetylase inhibitors (HDACis) show potential in cancer treatment.

Purpose of the Study:

  • To investigate the effect of trichostatin A (TSA) on HO8910 ovarian cancer cell differentiation.
  • To elucidate the molecular mechanisms underlying TSA-induced differentiation.
  • To explore the role of the epidermal growth factor receptor (EGFR) pathway in this process.

Main Methods:

  • Treatment of HO8910 ovarian cancer cells with trichostatin A (TSA).
  • Analysis of morphological changes, gene expression (FOXA2, SOX2, OCT4, p21Cip1, cyclin D1), and cell cycle progression.
  • Inhibition of the epidermal growth factor receptor (EGFR) signaling pathway.

Main Results:

  • TSA induced significant morphological changes indicative of differentiation in HO8910 cells.
  • TSA increased differentiation marker FOXA2 and decreased pluripotency markers SOX2 and OCT4.
  • TSA suppressed proliferation, caused G1 cell cycle arrest, elevated p21Cip1, and decreased cyclin D1.
  • Inhibition of the EGFR pathway potentiated TSA-induced differentiation.

Conclusions:

  • Trichostatin A (TSA) effectively induces differentiation in HO8910 ovarian cancer cells.
  • TSA impacts key markers of differentiation, pluripotency, and cell cycle regulation.
  • Combination therapy with TSA and EGFR inhibitors presents a promising strategy for ovarian cancer differentiation therapy.

More Related Videos

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Loss of Tumor Suppressor Gene Functions01:12

Loss of Tumor Suppressor Gene Functions

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...